Amgen Inc. stock (US0311621009): Weight-loss trial update keeps biotech giant in focus

Amgen Inc. stock has stayed in focus among healthcare investors after the company reiterated its development plans for the obesity candidate AMG 133 (also known as maridebart cafraglutide), keeping the biotech group in the competitive race for next?generation weight?loss drugs against leaders Novo Nordisk and Eli Lilly, according to management commentary in early May 2026 reported by Reuters as of 05/2026.

In the context of strong interest around GLP?1 therapies, Amgen has confirmed that a larger mid? to late?stage trial program is being prepared for AMG 133 after earlier phase 1b data showed meaningful weight reduction with a once?monthly injection schedule, as previously highlighted in company materials and recapped by STAT News as of 11/2022.

As of: 28.05.2026

By the editorial team – specialized in equity coverage.

Amgen Inc.: core business model

Amgen is one of the largest independent biotechnology companies globally, focusing on the discovery, development and commercialization of human therapeutics, with a portfolio that spans oncology, inflammation, bone health, cardiovascular disease and rare conditions, as described in its corporate overview on Amgen website as of 2025.

The company’s model is built around complex biologic drugs, including monoclonal antibodies and other protein?based therapies, many of which require sophisticated manufacturing processes and long development timelines, which can create high barriers to entry for competitors according to industry analyses referenced by Fierce Pharma as of 10/2024.

Amgen generates most of its revenue from a concentrated group of flagship products targeting serious diseases, complemented by a growing biosimilars franchise and late?stage pipeline assets that are intended to offset patent expirations in more mature drugs, based on commentary in recent investor presentations cited by Amgen investor relations as of 02/2025.

The company invests heavily in research and development to maintain a robust clinical pipeline, while also using business development, including acquisitions and licensing deals, to broaden its portfolio and enter new therapeutic areas, a strategy highlighted around the Horizon Therapeutics acquisition in reports from Bloomberg as of 10/2023.

Main revenue and product drivers for Amgen Inc.

Amgen’s revenue base is anchored by key drugs such as Enbrel for inflammatory diseases, Prolia and Xgeva in bone health, and Repatha, a PCSK9 inhibitor for lowering LDL cholesterol, which together have historically represented a significant portion of annual sales according to the company’s Form 10?K for 2024 published by Amgen investor relations as of 02/2025.

In oncology, products like Kyprolis, Blincyto and Lumakras contribute to growth and reflect Amgen’s push into targeted cancer therapies, with Lumakras being one of the first KRAS G12C inhibitors to reach the market, as described by the US Food and Drug Administration in a product approval notice referenced by FDA as of 05/2021.

The company has also built a biosimilars portfolio that includes alternatives to blockbuster biologics such as Humira and Avastin, providing a diversified stream of revenue in markets where payers and healthcare systems are sensitive to costs, a dynamic underlined in European market reports cited by Evaluate Pharma as of 09/2024.

Looking forward, pipeline candidates like AMG 133 in obesity and other investigational assets in oncology and inflammation are seen as important for maintaining long?term growth once older drugs face intensified biosimilar competition, according to portfolio discussions in recent earnings calls summarized by Seeking Alpha transcripts as of 05/2025.

Why Amgen Inc. matters for US investors

For US investors, Amgen is a core constituent of major healthcare and biotechnology indices and is widely held through exchange?traded funds and mutual funds that track the US large?cap market, as reflected in index composition data referenced by S&P Global as of 12/2024.

The company’s listing on Nasdaq under the ticker AMGN provides high liquidity and deep options markets, making the stock a frequent vehicle for expressing views on the broader biotech sector and on themes such as obesity treatments, oncology innovation and patent?cliff management, according to trading statistics discussed by Nasdaq as of 03/2025.

Amgen’s exposure to the US healthcare system, including Medicare and commercial insurers, means that policy shifts around drug pricing, reimbursement and biosimilars adoption can influence its earnings trajectory, a linkage assessed in sector policy notes cited by Morgan Stanley as of 01/2025.

Conclusion

Amgen Inc. remains a key player in global biotechnology with a diversified portfolio of established biologics, an expanding biosimilars business and a pipeline that includes an experimental obesity therapy, AMG 133, that keeps the company involved in one of the most closely watched drug markets. For investors, the stock combines exposure to mature cash?generating products with the uncertainties and potential upside of late?stage development assets in areas like oncology and metabolic disease. Future performance is likely to depend on how effectively Amgen manages competitive pressures on legacy brands, executes its clinical programs and navigates the evolving regulatory and pricing environment in the US and abroad.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.